News
Presentation of The NGAL Test data at the 30th International Symposium on Intensive Care and Emergency Medicine (ISICEM)
February 22 2010
TSIS 2010, March 9-13, Munich, Germany
February 18 2010
ToxExpo, March 7-11, Salt Lake City, Utah
February 16 2010
CRITICARE 2010, February 10-14, Hyderabad, India
January 25 2010
SCCM Annual Congress, January 9-13, Miami Beach, Florida
January 07 2010
BioPorto Diagnostics and ALPCO Diagnostics enter into partnership
December 02 2009
Product launch: Dog NGAL ELISA Kit (KIT 043)
November 16 2009
MEDICA, November 18-21, Düsseldorf, Germany
November 09 2009
BioPorto introduces The NGAL Test at the ASN Renal Week 2009, October 27 – November 1, San Diego
October 16 2009
Breakthrough test can prevent fatal kidney failure
September 21 2009
Breakthrough test can prevent fatal kidney failure
September 21 2009 by Ana Belén Enfedaque Buisán
BioPorto Diagnostics develops a diagnostic test that will help millions
Acute kidney injury has long been recognized as a devastating disorder which often arises as a complication of other serious illnesses.
Despite great efforts to understand and treat this condition the area has seen little or no improvement in over 60 years. Paradoxically, the incidence of this potentially deadly disorder has been rising during the last decades and is now reaching epidemic proportions. Each year, more than 13 million patients suffer acute kidney injury of which more than 30% have a fatal outcome.
With a move that will prove to be a major advance in the diagnosis of this growing number of affected patients, BioPorto Diagnostics have announced the successful development of a groundbreaking test called NGAL that can diagnose acute kidney injury. A test like this has been on the wish list of doctors worldwide for decades.
“The NGAL test has the potential to revolutionize the way kidney injury is managed” says Dr. Lars Otto Uttenthal, CSO of BioPorto Diagnostics. Existing methods of determining kidney injury do not provide useful information about the state of the patient until one to three days after an injury has occurred. In contrast, the NGAL test will reveal the occurrence of kidney injury within a few hours. “Doctors now have an opportunity to predict a patient’s outcome – they can take proactive steps at an early stage that will prevent kidney injury from turning into the very dangerous state of established kidney failure,” concludes Dr. Uttenthal.
“The icing on the cake is that the NGAL test is designed to be used on apparatus that already exists in laboratories and hospitals. In this way we have secured that the test will be affordable and readily available to doctors worldwide,” says Thea Olesen, CEO of BioPorto.
In a market that is estimated to be worth over a billion dollars, the NGAL test could grab a considerable share, solidifying BioPorto’s position as the leading player in the NGAL market. The new NGAL test is developed in collaboration with one of the world’s leading manufacturers of diagnostic tests and is currently being prepared for production.
The test will be presented in October at ASN Renal Week in San Diego - the yearly meeting point for kidney specialists from all over the world.
Further details
Thea Olesen, CEO, BioPorto
Telephone +45 45 29 00 00; e-mail info@bioporto.com
About BioPorto A/S
BioPorto develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefit of individual patients and to promote efficiency in the health sector. The Company’s developments include a patented test (NGAL) to diagnose and monitor acute kidney injury.
BioPorto was founded in 2000 and is listed on the NASDAQ OMX Copenhagen (symbol: BIOPOR). www.bioporto.com
